ArticleJournal for immunotherapy of cancer2019

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.

Alexandra S Zimmer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.